Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

Sponsor
Fujian Cancer Hospital
Study ID
NCT05595889
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Surufatinib — DRUG
    250 mg/day p.o. QD
  • Irinotecan — DRUG
    Participants will receive irinotecan，100 mg/m2，Intravenous drip, day 1 and day 8 of every 3 weeks

Study Details

To evaluate the clinical efficacy and safety of surufatinib combined with irinotecan in the second line treatment of small cell lung cancer.

Key Dates

Start date
Dec 1, 2022
Status verified
Nov 2022
Primary completion
Sep 30, 2024
Completion
Sep 30, 2025

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Surufatinib combined with irinotecan
    Surufatinib combined with irinotecan as a second-line treatment for small cell lung cancer

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months ]

Central Contacts

Related Studies